Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Hisun to collaborate in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China.

The companies have signed a memorandum of understanding on their intention to establish a joint venture with a focus on research, development and commercialisation of off-patent medicines to help build the presence of both firms in the country.

Both parties can contribute existing products and assets to provide a platform for the collaboration.

The move follows a similar agreement Pfizer signed with Chinese company Shanghai Pharmaceuticals, which included distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities.

According to Pfizer, branded generics account for 60 per cent of the domestic market in China, with the country expected to become the world's second-largest pharmaceutical market by 2015.

Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company. He said: "Collaborating with the world's leading pharmaceutical companies to form potential joint ventures is a strategy being adopted by Hisun."

6th June 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....